BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22038225)

  • 21. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
    Abd El-Maqsoud NM; Osman NA; Abd El-Hamid AM; Fath El-Bab TK; Galal EM
    Clin Genitourin Cancer; 2016 Apr; 14(2):e143-52. PubMed ID: 26794392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age?
    Bastian PJ; Ellinger J; Schmidt D; Wernert N; Wellmann A; Müller SC; von Rücker A
    Eur J Med Res; 2004 Nov; 9(11):523-7. PubMed ID: 15649863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
    Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
    Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression levels of heat shock protein 27 and cellular FLICE-like inhibitory protein in prostate cancer correlate with Gleason score sum and pathologic stage.
    Lee SW; Cho JM; Cho HJ; Kang JY; Kim EK; Yoo TK
    Korean J Urol; 2015 Jul; 56(7):505-14. PubMed ID: 26175869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Factors of Prostate Cancer in Tunisian Men: Immunohistochemical Study.
    Missaoui N; Abdelkarim SB; Mokni M; Hmissa S
    Asian Pac J Cancer Prev; 2016; 17(5):2655. PubMed ID: 27268646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
    Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
    PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
    Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
    Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
    Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer.
    Horvath LG; Henshall SM; Lee CS; Kench JG; Golovsky D; Brenner PC; O'Neill GF; Kooner R; Stricker PD; Grygiel JJ; Sutherland RL
    Int J Cancer; 2005 Jan; 113(3):415-22. PubMed ID: 15455387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
    Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
    Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Augmented immunoexpression of survivin correlates with parameters of aggressiveness in prostate cancer.
    Danilewicz M; Stasikowska-Kanicka O; Wągrowska-Danilewicz M
    Pol J Pathol; 2015 Mar; 66(1):44-8. PubMed ID: 26017879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate cancer antigen-1 as a potential novel marker for prostate cancer.
    Liu BQ; Wu YD; Li PH; Wei JX; Zhang T; Liu RL
    Asian J Androl; 2007 Nov; 9(6):821-6. PubMed ID: 17968469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic markers of prostate cancer: utility of prostate-specific antigen in diagnosis and staging.
    Lee CT; Oesterling JE
    Semin Surg Oncol; 1995; 11(1):23-35. PubMed ID: 7538692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
    Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
    Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinicopathologic patterns of prostatic diseases and prostate cancer in Saudi patients.
    Mosli HA; Abdel-Meguid TA; Al-Maghrabi JA; Kamal WK; Saadah HA; Farsi HM
    Saudi Med J; 2009 Nov; 30(11):1439-43. PubMed ID: 19882057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Underexpression of MMP-2 and its regulators, TIMP2, MT1-MMP and IL-8, is associated with prostate cancer.
    Reis ST; Antunes AA; Pontes-Junior J; Sousa-Canavez JM; Dall'Oglio MF; Piantino CB; Cruz JA; Morais DR; Srougi M; Leite KR
    Int Braz J Urol; 2012; 38(2):167-74. PubMed ID: 22555040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High Incidence of Incidental Prostate Cancer in Transurethral Resection of Prostate Specimens in China. The Value of Pathologic Review.
    Lin J; Yu X; Yang X; Jin J; Zhou L; Liu L; Su J; Li Y; Shang M
    Anal Quant Cytopathol Histpathol; 2016 Feb; 38(1):31-7. PubMed ID: 27363064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.